Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
NCT ID: NCT01228513
Last Updated: 2016-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
263 participants
INTERVENTIONAL
2010-11-30
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis
NCT00944632
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
NCT02118766
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333
A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis
NCT02795832
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
NCT01602341
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.01% ointment
Lowest concentration
ZK245186
Daily topical application
0.03% ointment
Middle concentration
ZK245186
Daily topical application
0.1% ointment
Highest concentration
ZK245186
Daily topical application
Placebo (vehicle without active)
No active ingredient
Placebo (vehicle without active ingredient)
Daily topical application
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZK245186
Daily topical application
Placebo (vehicle without active ingredient)
Daily topical application
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body surface area affected by atopic dermatitis at or less than 15% at start of treatment
Exclusion Criteria
* Conditions that may pose a threat to the patient or effect the outcome of the study
* Wide-spread atopic dermatitis (AD) requiring systemic treatment
* Immuno-compromized conditions
* At least 2 weeks after local AD treatment and treatment with systemic antibiotics
* At least 1 month after systemic AD treatment
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anaheim, California, United States
Honolulu, Hawaii, United States
Boise, Idaho, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Warren, Michigan, United States
Fridley, Minnesota, United States
New York, New York, United States
Portland, Oregon, United States
Austin, Texas, United States
College Station, Texas, United States
San Antonio, Texas, United States
Webster, Texas, United States
Kawaguchi Saitama, , Japan
Tokyo, , Japan
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1403380
Identifier Type: OTHER
Identifier Source: secondary_id
15267
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.